SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sleepman who wrote (632)4/26/1998 3:58:00 PM
From: RXGOLF  Read Replies (3) of 834
 
D.Root,

While doing a little research, I saw that Hoescht Marion Roussel has a product that is currently in the FDA approval process and close to marketing with the potential indication of Heparin thrombocytopenia. The generic name is Lepirudin, and the brand name is Refludan. Is this product a concern for Novastan?? I know nothing about Refludan except what I just posted. Please advise me of your thoughts.

Thanks, and good luck,
RXGOLF
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News